Kleener to Swallow $40 Billion Tylenol Makers in Largest Consumer Healthcare Deal. 
Kimberly-Clark has sealed a record-breaking agreement worth more than $40 billion to acquire Kenvue, the parent company of popular over-the-counter medicine brand Tylenol. The deal is set to give rise to a global consumer health giant with an expansive portfolio that includes household brands such as Kleenex and Huggies.
Kenvue's struggles mounted after former CEO was ousted in July. The company, which had been spun off from Johnson & Johnson two years prior, has faced sharp declines in stock market value amid mounting controversy over its products' potential health risks.
Notably, the parent of Tylenol faced intense scrutiny when Donald Trump claimed acetaminophen increases the risk of autism among children born to mothers who use it during pregnancy. In contrast to President Trump's assertion, scientific research and medical experts have consistently disputed this claim.
Kenvue has vigorously pushed back against these allegations, pointing out that 'sound science' indicates no causal link between taking Tylenol and autism. On a more somber note, the company also faces mounting lawsuits over claims its baby powder products contain carcinogens and caused cancer among users.
Despite the turmoil surrounding Kenvue's financials and controversies over some of its brands, Kimberly-Clark expressed confidence in achieving around $2.1 billion in annual cost savings from the deal when it is completed mid-next year.
				
			Kimberly-Clark has sealed a record-breaking agreement worth more than $40 billion to acquire Kenvue, the parent company of popular over-the-counter medicine brand Tylenol. The deal is set to give rise to a global consumer health giant with an expansive portfolio that includes household brands such as Kleenex and Huggies.
Kenvue's struggles mounted after former CEO was ousted in July. The company, which had been spun off from Johnson & Johnson two years prior, has faced sharp declines in stock market value amid mounting controversy over its products' potential health risks.
Notably, the parent of Tylenol faced intense scrutiny when Donald Trump claimed acetaminophen increases the risk of autism among children born to mothers who use it during pregnancy. In contrast to President Trump's assertion, scientific research and medical experts have consistently disputed this claim.
Kenvue has vigorously pushed back against these allegations, pointing out that 'sound science' indicates no causal link between taking Tylenol and autism. On a more somber note, the company also faces mounting lawsuits over claims its baby powder products contain carcinogens and caused cancer among users.
Despite the turmoil surrounding Kenvue's financials and controversies over some of its brands, Kimberly-Clark expressed confidence in achieving around $2.1 billion in annual cost savings from the deal when it is completed mid-next year.